Chapter 1 : Antiherpesviral DNA Polymerase Inhibitors

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Antiherpesviral DNA Polymerase Inhibitors, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap01-1.gif /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap01-2.gif


Acyclovir (ACV), whose mechanism is detailed in this chapter, heralded the second generation of antivirals for herpesviruses and set the standard for the development of antiviral drugs. Two limitations of oral acyclovir have been its limited oral bioavailability (~15%) and short half-life. These limitations require administration of large pills as often as every four hour. Valacyclovir and famciclovir overcome these limitations and would have completely displaced the use of acyclovir except for the expiration of the acyclovir patent resulting in the availability of low-cost generic drug. Both valacyclovir and famciclovir can be used for applications of oral acyclovir. In the herpesviruses considered here, there are six gene products with activities at the replication fork. The viral proteins that have thus far served as the best targets for antiherpesvirus drugs are the viral DNA polymerases that are required for viral DNA replication, which are thus targets for inhibition, and viral kinases. All of the nucleoside analogs discussed in this chapter are converted to analogs of deoxynucleoside triphosphates (dNTPs) that inhibit herpesvirus DNA polymerases. The mechanism of acyclovir action begins with the TK encoded by herpes simplex virus (HSV) or varicella-zoster virus (VZV). An important unanswered question is whether new antiherpesvirus drugs can be developed to combat drug-resistant human infections. Although the number of drug-resistant HSV infections is relatively small, the need for new drugs that are active against acyclovir-resistant viruses and that have good pharmacokinetic and toxicity profiles is substantial for the patients involved.

Citation: Coen D. 2009. Antiherpesviral DNA Polymerase Inhibitors, p 1-18. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch1
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1.
Figure 1.

Structures of antiviral nucleoside analogs. (A) Antiherpesvirus nucleoside analogs mimic the deoxynucleoside deoxyguanosine, except for cidofovir, which mimics the deoxynucleotide dCMP. The compounds shown here all contain acyclic moieties that mimic deoxyribose. Valacyclovir and famciclovir are prodrugs of acyclovir and penciclovir, respectively. (B) Foscarnet is a pyrophosphate analog that inhibits viral polymerases. It is approved for treatment of HSV and HCMV infections that are resistant to other drugs.

Citation: Coen D. 2009. Antiherpesviral DNA Polymerase Inhibitors, p 1-18. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Herpesvirus replication cycle. (a) Attachment and entry. Virion envelope proteins attach to cellular receptors on the plasma membrane and then initiate fusion of the two membranes. Nucleocapsids containing the viral genome (hexagons) are liberated into the cytoplasm and transported to nuclear pores. Viral DNA is released into the nucleus, where it circularizes. (b) Transcription. The DNA is transcribed by host RNA polymerase II with the aid of virally encoded factors, giving rise to three classes of viral transcripts that are then translated in the cytoplasm into three classes of viral proteins: immediate early, early, and late. Immediate early proteins typically participate in transcription of the viral DNA. (c) DNA replication. Early proteins typically participate in viral DNA replication. (d) Assembly, encapsidation, and nuclear egress. Late proteins typically participate in assembly of capsids into which replicated DNA is encapsidated. The prevailing model is that the resulting nucleocapsids leave the nucleus by budding through the inner nuclear membrane and then through a complex process of de-envelopment and reenvelopment egress from the cell. Adapted from reference with permission.

Citation: Coen D. 2009. Antiherpesviral DNA Polymerase Inhibitors, p 1-18. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

Mechanism of action of acyclovir. (A) Acyclovir is selectively phosphorylated by HSV or VZV thymidine kinase to generate acyclovir monophosphate. Host cellular enzymes then sequentially phosphorylate the drug monophosphate to the di-phosphate and triphosphate (pppACV) forms. (B) Acyclovir triphosphate has a three-step mechanism of inhibition of herpesvirus DNA polymerase in vitro: ( ) the drug triphosphate acts as a competitive inhibitor of dGTP (pppdG) binding; ( ) the drug triphosphate acts as a substrate and is incorporated into the growing DNA chain across from deoxycytidine in the template, terminating elongation; and ( ) the polymerase becomes trapped on the acyclovir-terminated DNA chain when the dNTP binds (here shown as pppdC, dCTP, which would be templated by deoxyguanosine). Modified from reference with permission.

Citation: Coen D. 2009. Antiherpesviral DNA Polymerase Inhibitors, p 1-18. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Aduma, P. P.,, M. C. Connelly,, R. V. Srinivas, and, A. Fridland. 1995. Metabolic diversity and antiviral activities of acyclic nucleo-side phosphonates. Mol. Pharmacol. 47:816822.
2. Appleton, B. A.,, A. Loregian,, D. J. Filman,, D. M. Coen, and, J. M. Hogle. 2004. The cytomegalovirus DNA polymerase subunit UL44 forms a C clamp-shaped dimer. Mol. Cell 15:233244.
3. Ashton, W. T.,, J. D. Karkas,, A. K. Field, and, R. L. Tolman. 1982. Activation by thymidine kinase and potent antiherpetic activity of 2’-no‘2’-deoxyguanosine (2’NDG). Biochem. Biophys. Res. Commun. 108:17161721.
4. Azzeh, M.,, A. Honigman,, A. Taraboulos,, A. Rouvinski, and, D. G. Wolf. 2006. Structural changes in human cytomegalovirus cytoplasmic assembly sites in the absence of UL97 kinase activity. Virology 354:6979.
5. Baek, M.-C.,, P. M. Krosky, and, D. M. Coen. 2002. The relationship between autophosphorylation and phosphorylation of exogenous substrates by the human cytomegalovirus UL97 protein kinase. J. Virol. 76:1194311952.
6. Baek, M.-C.,, P. M. Krosky,, Z. He, and, D. M. Coen. 2002. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase: importance of the P + 5 position. J. Biol. Chem. 277:2959329599.
7. Baldanti, F.,, N. Lurain, and, G. Gerna. 2004. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum. Immunol. 65:403409.
8. Baldanti, F.,, E. Silini,, A. Sarasini,, C. L. Talarico,, S. C. Stanat,, K. K. Biron,, M. Furione,, F. Bono,, G. Palu, and, G. Gerna. 1995. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol. 69:796800.
9. Baldanti, F.,, M. R. Underwood,, S. C. Stanat,, K. K. Biron,, S. Chou,, A. Sarasini,, E. Silini, and, G. Gerna. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:13901395.
10. Bernad, A.,, L. Blanco,, J. M. Lazaro,, G. Martin, and, M. Salas. 1989. A conserved 3’-5’ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell 59:219228.
11. Besecker, M. I.,, C. L. Furness,, D. M. Coen, and, A. Griffiths. 2007. Expression of extremely low levels of thymidine kinase from an acyclovir-resistant herpes simplex virus mutant supports reactivation from latently infected mouse trigeminal ganglia. J. Virol. 81:83568360.
12. Beutner, K. R.,, D. J. Friedman,, C. Forszpaniak,, P. L. Andersen, and, M. J. Wood. 1995. Valciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39:15461553.
13. Bird, L. E.,, J. Ren,, A. Wright,, K. D. Leslie,, B. Degrève,, J. Balzarini, and, D. K. Stammers. 2003. Crystal structure of varicella zoster virus thymidine kinase. J. Biol. Chem. 278:2468024687.
14. Biron, K. K.,, J. A. Fyfe,, J. E. Noblin, and, G. B. Elion. 1982. Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus. Am. J. Med. 73:383386.
15. Biron, K. K.,, J. A. Fyfe,, S. C. Stanat,, L. K. Leslie,, J. B. Sorrell,, C. U. Lambe, and, D. M. Coen. 1986. A human cytomegalovirus mutant resistant to the nucleoside analog, 9-([2-hydroxy-1-(hydr oxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. USA 83:87698773.
16. Biron, K. K.,, R. J. Harvey,, S. C. Chamberlain,, S. S. Good,, A. A. Smith,, M. G. Davis,, C. L. Talarico,, R. Ferris,, R. E. Dornsife,, S. C. Stanat,, J. C. Drach,, L. B. Townsend, and, G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:23652372.
17. Biron, K. K.,, S. C. Stanat,, J. B. Sorrell,, J. A. Fyfe,, P. M. Keller,, C. U. Lambe, and, D. J. Nelson. 1985. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]meth yl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82:24732477.
18. Boyd, M. R.,, S. Safrin, and, E. R. Kern. 1993. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir. Chem. Chemother. 4:311.
19. Brown, D. G.,, R. Visse,, G. Sandhu,, A. Davies,, P. J. Rizkallah,, C. Melitz,, W. C. Summers, and, M. R. Sanderson. 1995. Crystal structures of the thymidine kinase from herpes simplex virus type 1 in complex with deoxythymidine and ganciclovir. Nat. Struct. Biol. 2:876880.
20. Champness, J. N.,, M. S. Bennett,, F. Wien,, R. Visse,, W. C. Summers,, P. Herdewijn,, E. De Clercq,, T. Ostrowski,, R. L. Jarvest, and, M. R. Sanderson. 1998. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins 32:350361.
21. Chee, M. S.,, G. L. Lawrence, and, B. G. Barrell. 1989. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Virol. 70:11511160.
22. Chen, S.-H.,, W. J. Cook,, K. L. Grove, and, D. M. Coen. 1998. Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant. J. Virol. 72:67106715.
23. Cheng, Y.-C.,, E.-S. Huang,, J.-C. Lin,, E.-C. Mar,, J. S. Pagano,, G. Dutschman, and, S. Grill. 1983. Unique spectrum of activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA 80:27672770.
24. Cherrington, J. M.,, S. J. Allen,, B. H. McKee, and, M. S. Chen. 1994. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases β and γ. Biochem. Pharmacol. 48:19861988.
25. Chiou, H. C.,, K. Kumura,, A. Hu,, K. M. Kerns, and, D. M. Coen. 1995. Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene. Antivir. Chem. Chemother. 6:281288.
26. Cihlar, T.,, M. D. Fuller,, A. S. Mulato, and, J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382393.
27. Cihlar, T.,, I. Votruba,, K. Horska, and, R. Liboska. 1992. Metabolism of 1-(S)-(3-hydroxy-2-phosphonomethoxypropyl)cytosine (HPMPC) in human embryonic lung cells. Collect. Czech. Chem. Commun. 57:661672.
28. Coen, D. M. 1994. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol. 2:481485.
29. Coen, D. M. 1996. Herpes simplex virus and varicella zoster virus: nucleosides and foscarnet—mechanisms, p. 81–102. In D. Rich-man (ed.), Antiviral Drug Resistance. John Wiley & Sons, Chichester, United Kingdom.
30. Coen, D. M. 1991. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antivir. Res. 15:287300.
31. Coen, D. M. 1996. Viral DNA polymerases, p. 495–523. In M. DePamphilis (ed.), DNA Replication in Eukaryotic Cells. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
32. Coen, D. M.,, A. F. Irmiere,, J. G. Jacobson, and, K. M. Kerns. 1989. Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168:221231.
33. Coen, D. M.,, M. Kosz-Vnenchak,, J. G. Jacobson,, D. A. Leib,, C. L. Bogard,, P. A. Schaffer,, K. L. Tyler, and, D. M. Knipe. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA 86:47364740.
34. Coen, D. M., and, D. D. Richman. 2007. Antiviral agents, p. 447–485. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields Virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
35. Coen, D. M., and, P. A. Schaffer. 2003. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discov. 2:278288.
36. Coen, D. M., and, P. A. Schaffer. 1980. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA 77:22652269.
37. Cohen, J. I.,, S. E. Straus, and, A. M. Arvin. 2007. Varicella-zoster virus replication, pathogenesis, and management, p. 2773–2818. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, S. E. Straus, M. A. Martin, and B. Roizman (ed.), Fields Virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
38. Crumpacker, C. S.,, L. E. Schnipper,, J. A. Zaia, and, M. J. Levin. 1979. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob. Agents Chemother. 15:642645.
39. Darby, G.,, B. A. Larder, and, M. M. Inglis. 1986. Evidence that the ‘active centre’ of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the poly-peptide. J. Gen. Virol. 67:753758.
40. Derse, D.,, K. F. Bastow, and, Y. Cheng. 1982. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. J. Biol. Chem. 257:1025110260.
41. Doublié, S.,, S. Tabor,, A. M. Long,, C. C. Richardson, and, T. Ellenberger. 1998. Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 Å resolution. Nature 391:251258.
42. Douglas, J. M.,, C. Critchlow,, J. Benedetti,, G. J. Mertz,, J. D. Connor,, M. A. Hintz,, A. Fahnlander,, M. Remington,, C. Winter, and, L. Corey. 1984. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. 310:15511556.
43. Dunkle, L. M.,, A. M. Arvin,, R. J. Whitley,, H. A. Rotbart,, H. M. Feder, Jr.,, S. Feldman,, A. A. Gershon,, M. L. Levy,, G. F. Hayden, and, P. V. McGuirt. 1991. A controlled trial of acyclovir for chick-enpox in normal children. N. Engl. J. Med. 325:15391544.
44. Earnshaw, D. L.,, T. H. Bacon,, S. J. Darlison,, K. Edmonds,, R. M. Perkins, and, R. A. Vere Hodge. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36:27472757.
45. Efstathiou, S.,, S. Kemp,, G. Darby, and, A. C. Minson. 1989. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J. Gen. Virol. 70:869879.
46. Elion, G. B.,, P. A. Furman,, J. A. Fyfe,, P. de Miranda,, L. Beauchamp, and, H. J. Schaeffer. 1977. Selectivity of action of an anti-herpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA 74:57165720.
47. Ellis, M. N.,, R. Waters,, E. L. Hill,, D. C. Lobe,, D. W. Selleseth, and, D. W. Barry. 1989. Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1. Antimicrob. Agents Chemother. 33:304310.
48. Eriksson, B., and, B. Oberg. 1979. Characteristics of herpes virus mutants resistant to phosphonoformate and phosphonacetate. Antimicrob. Agents Chemother. 15:758762.
49. Eriksson, B.,, B. Öberg, and, B. Wahren. 1982. Pyrophosphate analogs as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim. Biophys. Acta 696:115123.
50. Ertl, P.,, W. Snowden,, D. Lowe,, W. Miller, and, E. Littler. 1995. A comparative study of the in vitro and in vivo antiviral activities of aciclovir and penciclovir. Antivir. Chem. Chemother. 6:8997.
51. Field, H. J. 1982. Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy. Anti-microb. Agents Chemother. 21:744752.
52. Field, H. J., and, E. Lay. 1984. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir. Antivir. Res. 4:4352.
53. Field, H. J., and, P. Wildy. 1978. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J. Hyg. 81:267277.
54. Foti, M.,, S. Marshalko,, E. Schurter,, S. Kumar,, G. P. Beardsley, and, B. I. Schweitzer. 1997. Solution structure of a DNA decamer containing the antiviral drug ganciclovir: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement. Biochemistry 36:53365345.
55. Franklin, M. C.,, J. Wang, and, T. A. Steitz. 2001. Structure of the replicating complex of a pol α family DNA polymerase. Cell 105:657667.
56. Freitas, V. R.,, D. F. Smee,, M. Chernow,, R. Boehme, and, T. R. Matthews. 1985. Activity of 9-(1,3-dihydroxy-2-propoxymethyl) guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob. Agents Chemother. 28:240245.
57. Furman, P. A.,, P. de Miranda,, M. H. St. Clair, and, G. B. Elion. 1981. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob. Agents Chemother. 20:518524.
58. Germershausen, J.,, R. Bostedor,, A. K. Field,, H. Perry,, R. Liou,, H. Bull,, R. L. Tolman, and, J. D. Karkas. 1983. A comparison of the antiviral agents 2’-nor-2’-deoxyguanosine and acyclovir: uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphates. Biochem. Biophys. Res. Commun. 116:360367.
59. Gibbs, J. S.,, H. C. Chiou,, K. F. Bastow,, Y. C. Cheng, and, D. M. Coen. 1988. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc. Natl. Acad. Sci. USA 85:66726676.
60. Gibbs, J. S.,, H. C. Chiou,, J. D. Hall,, D. W. Mount,, M. J. Retondo,, S. K. Weller, and, D. M. Coen. 1985. Sequence and mapping analyses of the herpes simplex virus DNA polymerase gene predict a C-terminal substrate binding domain. Proc. Natl. Acad. Sci. USA 82:79697973.
61. Gilbert, C.,, J. Bestman-Smith, and, G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updates 5:88114.
62. Grey, F.,, M. Sowa,, P. Collins,, R. J. Fenton,, W. Harris,, W. Snowden,, S. Efstathiou, and, G. Darby. 2003. Characterization of a neuro-virulent aciclovir-resistant variant of herpes simplex virus. J. Gen. Virol. 84:14031410.
63. Griffiths, A.,, S.-H. Chen,, B. C. Horsburgh, and, D. M. Coen. 2003. Translational compensation of a frameshift mutation affecting herpes simplex virus thymidine kinase is sufficient to permit reactivation from latency. J. Virol. 77:47034709.
64. Griffiths, A., and, D. M. Coen. 2005. An unusual internal ribo-some entry sequence in the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA 102:96679772.
65. Griffiths, A., and, D. M. Coen. 2003. High-frequency phenotypic reversion and pathogenicity of an acyclovir-resistant herpes simplex virus mutant. J. Virol. 77:22822286.
66. Griffiths, A.,, M. A. Link,, C. L. Furness, and, D. M. Coen. 2006. Low-level expression and reversion both contribute to reactivation of herpes simplex virus drug-resistant mutants with mutations on homopolymeric sequences in thymidine kinase. J. Virol. 80:65686574.
67. Hall, J. D.,, P. A. Furman,, M. H. St. Clair, and, C. W. Knopf. 1985. Reduced in vivo mutagenesis by mutant herpes simplex DNA polymerase involves improved nucleotide selection. Proc. Natl. Acad. Sci. USA 82:38893993.
68. Hall, J. D.,, K. L. Orth,, K. L. Sander,, B. M. Swihart, and, R. A. Senese. 1995. Mutations within conserved motifs in the 3’-5’ exonuclease domain of herpes simplex virus DNA polymerase. J. Gen. Virol. 76:29993008.
69. Hamirally, S.,, W. Jahng,, M. Baek,, R. R. Rando, and, D. M. Coen. 2004. A role for the HCMV UL97 protein kinase in virus-induced alterations in the nuclear lamina component, lamin A/C, and annexin I, p. 5.04. In Proceedings of the 29th International Herpesvirus Workshop, Reno, NV.
70. Hamirally, S.,, J. P. Kamil,, Y. M. Ndassa-Colday,, A. J. Lin,, W. J. Jahng,, M.-C. Baek,, S. Noton,, L. A. Silva,, M. Simpson-Holley,, D. M. Knipe,, D. E. Golan,, J. A. Marto, and, D. M. Coen. 2009. Viral mimicry of cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 5:e1000275.doi:10.1371/journal.ppat.1000275.
71. Hanks, S. K., and, T. Hunter. 1995. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9:576596.
72. Hannah, J.,, R. L. Tolman,, J. D. Karkas,, R. Liou,, H. C. Perry, and, A. K. Field. 1989. Carba-acyclonucleoside antiherpetic agents. J. Heterocyclic Chem. 26:12611271.
73. Hanson, M. N.,, L. C. Preheim,, S. Chou,, C. L. Talarico,, K. K. Biron, and, A. Erice. 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39:12041205.
74. Hardie, D. G. 1995. Cellular functions of protein kinases. In D. G. Hardie and S. Hanks (ed.), The Protein Kinase Facts Book, vol. 1. Academic Press, London, United Kingdom.
75. Harrison, P. T.,, R. Thompson, and, A. J. Davison. 1991. Evolution of herpesvirus thymidine kinases from cellular deoxycytidine kinase. J. Gen. Virol. 72:25832586.
76. He, Z.,, Y.-S. He,, Y. Kim,, L. Chu,, C. Ohmstede,, K. K. Biron, and, D. M. Coen. 1997. The human cytomegalovirus UL97 protein is a protein kinase that phosphorylates on serines and threonines. J. Virol. 71:405411.
77. Ho, H.-T.,, K. L. Woods,, J. J. Bronson,, H. De Boeck,, J. C. Martin, and, M. J. M. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl] cytosine. Mol. Pharmacol. 41:197202.
78. Horsburgh, B. C.,, S.-H. Chen,, A. Hu,, G. B. Mulamba,, W. H. Burns, and, D. M. Coen. 1998. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis? J. Infect. Dis. 178:618625.
79. Horsburgh, B. C.,, H. Kollmus,, H. Hauser, and, D. M. Coen. 1996. Translational recoding induced by G-rich mRNA sequences that form unusual structures. Cell 86:949959.
80. Huang, L.,, K. K. Ishii,, H. Zuccola,, A. M. Gehring,, C. B. C. Hwang,, J. Hogle, and, D. M. Coen. 1999. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of α-like DNA polymer-ases. Proc. Natl. Acad. Sci. USA 96:447452.
81. Huff, J. C.,, B. Bean,, H. H. Balfour, Jr.,, O. L. Laskin,, J. D. Connor,, L. Corey,, Y. J. Bryson, and, P. McGuirt. 1988. Therapy of herpes zoster with oral acyclovir. Am. J. Med. 85:8489.
82. Hume, A. J.,, J. S. Finkel,, J. P. Kamil,, D. M. Coen,, M. R. Culbertson, and, R. F. Kalejta. 2008. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320:797799.
83. Hwang, C. B., and, H. J. Chen. 1995. An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase. Gene 152:191193.
84. Hwang, C. B. C.,, B. Horsburgh,, E. Pelosi,, S. Roberts,, P. Digard, and, D. M. Coen. 1994. A net +1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant. Proc. Natl. Acad. Sci. USA 91:54615465.
85. Hwang, Y. T.,, B.-Y. Liu,, D. M. Coen, and, C. B. C. Hwang. 1997. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J. Virol. 71:77917798.
86. Ilsley, D. D.,, S.-H. Lee,, W. H. Miller, and, R. D. Kuchta. 1995. Acyclic guanosine analogues inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry 34:25042510.
87. Irmiere, A. F.,, M. M. Manos,, J. G. Jacobson,, J. S. Gibbs, and, D. M. Coen. 1989. Effect of an amber mutation in the herpes simplex virus thymidine kinase gene on polypeptide synthesis and stability. Virology 168:210220.
88. Kamil, J. P., and, D. M. Coen. 2007. Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phospho-protein pp65. J. Virol. 81:1065910668.
89. Kariya, M.,, S. Mori, and, Y. Eizuru. 2000. Comparison of human cytomegalovirus DNA polymerase activity for ganciclovir-resistant and -sensitive clinical strains. Antivir. Res. 45:115122.
90. Kaufman, H.,, E. L. Martola, and, C. Dohlman. 1962. Use of 5-iodo-2’-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch. Ophthalmol. 68:235239.
91. Knighton, D. R.,, J. Zheng,, L. F. Ten Eyck,, V. A. Ashford,, N.-H. Xuong,, S. S. Taylor, and, J. M. Sowadski. 1991. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253:407414.
92. Knighton, D. R.,, J. Zheng,, L. F. Ten Eyck,, N.-H. Xuong,, S. S. Taylor, and, J. M. Sowadski. 1991. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253:414420.
93. Komazin-Meredith, G.,, R. Mirchev,, D. E. Golan,, A. M. van Oijen, and, D. M. Coen. 2008. Hopping of a processivity factor on DNA revealed by single-molecule assays of diffusion. Proc. Natl. Acad. Sci. USA 105:1072110726.
94. Krosky, P. M.,, M.-C. Baek,, W. J. Jahng,, I. Barrera,, R. J. Harvey,, K. K. Biron,, D. M. Coen, and, P. B. Sethna. 2003. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77:77207727.
95. Krosky, P. M.,, M. C. Baek, and, D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905914.
96. Kühn, F. J. P., and, C. W. Knopf. 1996. Herpes simplex virus type 1 DNA polymerase: mutational analysis of the 3’-5’ exonuclease domain. J. Biol. Chem. 271:2924529254.
97. Larder, B. A., and, G. Darby. 1984. Virus drug-resistance: mechanisms and consequences. Antivir. Res. 4:142.
98. Larder, B. A.,, S. D. Kemp, and, G. Darby. 1987. Related functional domains in virus DNA polymerases. EMBO J. 6:169175.
99. Littler, E.,, A. D. Stuart, and, M. S. Chee. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160162.
100. Liu, S.,, J. D. Knafels,, J. S. Chang,, G. A. Waszak,, E. T. Baldwin,, M. R. Deibel, Jr.,, D. R. Thomsen,, F. L. Homa,, P. A. Wells,, M. C. Tory,, R. A. Poorman,, H. Gao,, X. Qiu, and, A. P. Seddon. 2006. Crystal structure of the herpes simplex virus 1 DNA polymerase. J. Biol. Chem. 281:1819318200.
101. Lowe, D. M.,, W. K. Alderton,, M. R. Ellis,, V. Parmar,, W. H. Miller,, G. B. Roberts,, J. A. Fyfe,, R. Gaillard,, P. Ertl,, W. Snowden, and, E. Littler. 1995. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother. 39:18021808.
102. Lurain, N. S.,, L. E. Spafford, and, K. D. Thompson. 1994. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:44274431.
103. Lurain, N. S.,, K. D. Thompson,, E. W. Holmes, and, G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:71467152.
104. Mar, E. C.,, J. F. Chiou,, Y. C. Cheng, and, E. S. Huang. 1985. Human cytomegalovirus-induced DNA polymerase and its interaction with the triphosphates of 1-(2’-deoxy-2’-fluoro-beta-D-arabinofuranosyl)-5-methyluracil, -5-iodocytosine, and -5-methylcytosine. J. Virol. 56:846851.
105. Marschall, M.,, M. Freitag,, P. Suchy,, D. Romaker,, R. Kupfer,, M. Hanke, and, T. Stamminger. 2003. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311:6071.
106. Marschall, M.,, A. Marzi,, P. aus dem Siepen,, R. Jochmann,, M. Kalmer,, S. Auerochs,, P. Lischka,, M. Leis, and, T. Stamminger. 2005. Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J. Biol. Chem. 280:3335733367.
107. Martin, J. C.,, C. A. Dvorack,, D. E. Smee,, T. R. Matthews, and, J. P. H. Verheyden. 1983. 9-[(1,3-dihydroxy-2-propoxy) methyl]guanine: a new potent and selective antiherpesvirus agent. J. Med. Chem. 26:759761.
108. Martin, J. L.,, C. E. Brown,, N. Matthews-Davis, and, J. E. Rear-don. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:27432749.
109. McGeoch, D. J.,, L. J. Coulter, and, H. W. M. Moss. 1995. Ul protein kinases (Herpesviruses), p. 391–393. In D. G. Hardie and S. Hanks (ed.), The Protein Kinase Facts Book, vol. 1. Academic Press, London, United Kingdom.
110. McGuirt, P. V.,, J. E. Shaw,, G. B. Elion, and, P. A. Furman. 1984. Identification of small DNA fragments synthesized in herpes simplex virus-infected cells in the presence of acyclovir. Antimicrob. Agents Chemother. 25:507509.
111. Mertz, G. J.,, C. W. Critchlow,, J. Benedetti,, R. C. Reichman,, R. Dolin,, J. Connor,, D. C. Redfield,, M. C. Savoia,, D. D. Rich-man, and, D. L. Tyrrell. 1984. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 252:11471151.
112. Metzger, C.,, D. Michel,, K. Schneider,, A. Luske,, H. J. Schlicht, and, T. Mertens. 1994. Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus. J. Virol. 68:84238427.
113. Miller, W. H., and, R. L. Miller. 1982. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem. Pharmacol. 31:38793884.
114. Miller, W. H., and, R. L. Miller. 1980. Phosphorylation of acyclovir monophosphate by GMP kinase. J. Biol. Chem. 255:72047207.
115. Mindel, A.,, A. Faherty,, O. Carney,, G. Patou,, M. Freris, and, P. Williams. 1988. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet i:926928.
116. Mocarski, E. S., Jr.,, T. Shenk, and, R. F. Pass. 2007. Cytomegalo-viruses, p. 2701–2772. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields Virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
117. Moore, M. R.,, F. M. Hamzeh,, F. E.-H. Lee, and, P. S. Lietman. 1994. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. Antimicrob. Agents Chemother. 38:24042408.
118. Nilsen, A. E.,, T. Aasen,, A. M. Halsos,, B. R. Kinge,, E. A. Tjotta,, K. Wikstrom, and, A. P. Fiddian. 1982. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet ii:571573.
119. Noble, S., and, D. Faulds. 1998. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56:115146.
120. Ostrander, M., and, Y.-C. Cheng. 1980. Properties of herpes simplex virus type 1 and type 2 DNA polymerase. Biochim. Biophys. Acta 609:232245.
121. Pelosi, E.,, K. A. Hicks,, S. L. Sacks, and, D. M. Coen. 1992. Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. Adv. Exp. Med. Biol. 312:151158.
122. Pelosi, E.,, G. B. Mulamba, and, D. M. Coen. 1998. Penciclovir and pathogenesis phenotypes of drug-resistant herpes simplex virus mutants. Antivir. Res. 37:1728.
123. Prichard, M. N.,, W. J. Britt,, S. L. Daily,, C. B. Hartline, and, E. R. Kern. 2005. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 79:1549415502.
124. Prichard, M. N.,, N. Gao,, S. Jairath,, G. Mulamba,, P. Krosky,, D. M. Coen,, B. O. Parker, and, G. S. Pari. 1999. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:56635670.
125. Prichard, M. N.,, E. Sztul,, S. L. Daily,, A. L. Perry,, S. L. Frederick,, R. B. Gill,, C. B. Hartline,, D. N. Streblow,, S. M. Varnum,, R. D. Smith, and, E. R. Kern. 2008. Human cytomegalovirus UL97 kinase is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J. Virol. 82:50545067.
126. Pue, M. A., and, L. Z. Benet. 1993. Pharmacokinetics of famciclovir in man. Antivir. Chem. Chemother. 4:4755.
127. Randell, J. C., and, D. M. Coen. 2001. Linear diffusion on DNA despite high-affinity binding by a DNA polymerase processivity factor. Mol. Cell 8:911920.
128. Reardon, J. E. 1989. Herpes simplex virus type 1 and human DNA polymerase interactions with 2’-deoxyguanosine-5’-tri-phosphate analogues. J. Biol. Chem. 264:1903919044.
129. Reardon, J. E., and, T. Spector. 1989. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir tri-phosphate. J. Biol. Chem. 264:74057411.
130. Reichman, R. C.,, G. J. Badger,, G. J. Mertz,, L. Corey,, D. D. Rich-man,, J. D. Connor,, D. Redfield,, M. C. Savoia,, M. N. Oxman, and, Y. Bryson. 1984. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 251:21032107.
131. Reid, R.,, E. C. Mar,, E. S. Huang, and, M. D. Topal. 1988. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate. J. Biol. Chem. 263:38983904.
132. Roizman, B.,, D. M. Knipe, and, R. J. Whitley. 2007. Herpes simplex viruses, p. 2502–2601. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, S. E. Straus, M. A. Martin, and B. Roizman (ed.),Fields Virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
133. Sacks, S. L.,, R. J. Wanklin,, D. E. Reece,, K. A. Hicks,, K. L. Tyler, and, D. M. Coen. 1989. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann. Intern. Med. 111:893899.
134. Safrin, S. 1996. Herpes simplex virus and varicella zoster virus: nucleosides and foscarnet—clinical aspects, p. 103–122. In D. D. Richman (ed.), Antiviral Drug Resistance. John Wiley & Sons, Chichester, United Kingdom.
135. Sarisky, R. T.,, T. T. Nguyen,, K. E. Duffy,, R. J. Wittrock, and, J. J. Leary. 2000. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 44:15241529.
136. Sarisky, R. T.,, M. R. Quail,, P. E. Clark,, T. T. Nguyen,, W. S. Halsey,, R. J. Wittrock,, J. O. Bartus,, M. M. Van Horn,, G. M. Sathe,, S. Van Horn,, M. D. Kelly,, T. H. Bacon, and, J. J. Leary. 2001. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J. Virol. 75:17611769.
137. Sasadeusz, J. J., and, S. L. Sacks. 1996. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type 2 herpes simplex virus: masked heterogeneity or reversion? J. Infect. Dis. 174:476482.
138. Sedarati, F.,, R. T. Javier, and, J. G. Stevens. 1988. Pathogenesis of a lethal mixed infection in mice with two nonneuroinvasive herpes simplex virus strains. J. Virol. 62:30373039.
139. Smee, D. F.,, J. C. Martin,, J. P. H. Verheyden, and, T. R. Matthews. 1983. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2propoxymethyl)guanine. Antimicrob. Agents Chemother. 23:676682.
140. Smith, K. O.,, K. S. Galloway,, W. L. Kennell,, K. K. Ogilvie, and, B. Radatus. 1982. A new nucleoside analog, 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 22:5561.
141. St. Clair, M. H.,, W. H. Miller,, R. L. Miller,, C. U. Lambe, and, P. A. Furman. 1984. Inhibition of cellular α DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U. Antimicrob. Agents Chemother. 25:191194.
142. Straus, S. E.,, K. D. Croen,, M. H. Sawyer,, A. G. Freifeld,, J. M. Felser,, J. K. Dale,, H. A. Smith,, C. Hallahan, and, S. N. Lehrman. 1988. Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. JAMA 260:22272230.
143. Sullivan, V.,, K. K. Biron,, C. Talarico,, S. C. Stanat,, M. Davis,, L. M. Pozzi, and, D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:1925.
144. Sullivan, V., and, D. M. Coen. 1991. Isolation of foscarnet-resistant human cytomegalovirus: patterns of resistance and sensitivity to other antiviral drugs. J. Infect. Dis. 164:781784.
145. Sullivan, V.,, C. L. Talarico,, S. C. Stanat,, M. Davis,, D. M. Coen, and, K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162164.
146. Suzutani, T.,, K. Ishioka,, E. De Clercq,, K. Ishibashi,, H. Kaneko,, T. Kira,, K.-I. Hashimoto,, M. Ogasawara,, K. Ohtani,, N. Wakamiya, and, M. Saijo. 2003. Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir and penciclovir. Antimicrob. Agents Chemother. 47:17071713.
147. Talarico, C. L.,, T. C. Burnette,, W. H. Miller,, S. L. Smith,, M. G. Davis,, S. C. Stanat,, T. I. Ng,, Z. He,, D. M. Coen,, B. Roizman, and, K. K. Biron. 1999. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Che-mother. 43:19411946.
148. Tenser, R. B., and, W. A. Edris. 1987. Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus after in vivo complementation. J. Virol. 61:21712174.
149. Tenser, R. B.,, R. L. Miller, and, F. Rapp. 1979. Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus. Science 205:915917.
150. Tenser, R. B.,, S. Ressel, and, M. E. Dunstan. 1981. Herpes simplex virus thymidine kinase expression in trigeminal ganglion infection: correlation of enzyme activity with ganglion virus titer and evidence of in vivo complementation. Virology 112:328341.
151. Tyring, S.,, R. A. Barbarash,, J. E. Nahlik,, A. Cunningham,, J. Marley,, M. Heng,, T. Jones,, T. Rea,, R. Boon, and, R. Saltzman. 1995. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann. Intern. Med. 123:8996.
152. Vere Hodge, R. A., and, Y.-C. Cheng. 1993. The mode of action of penciclovir. Antivir. Chem. Chemother. 4:1324.
153. Wald, A.,, L. Corey,, R. Cone,, A. Hobson,, G. Davis, and, J. Zeh. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Investig. 99:10921097.
154. Wang, J.,, A. K. Sattar,, C. C. Wang,, J. D. Karam,, W. H. Konigsberg, and, T. A. Steitz. 1997. Crystal structure of a pol α family replication DNA polymerase from bacteriophage RB69. Cell 89:10871099.
155. Wang, K.,, G. Mahalingam,, S. E. Hoover,, E. K. Mont,, S. M. Holland,, J. I. Cohen, and, S. E. Straus. 2007. Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and ganglia. J. Virol. 81:68176826.
156. Wang, T. S. F. 1996. Cellular DNA polymerases, p. 461–493. In M. L. DePamphilis (ed.), DNA Replication in Eukaryotic Cells. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
157. Weisshart, K.,, A. A. Kuo,, G. R. Painter,, L. L. Wright,, P. A. Furman, and, D. M. Coen. 1993. Conformational changes induced in herpes simplex virus DNA polymerase upon DNA binding. Proc. Natl. Acad. Sci. USA 90:10281032. (Erratum, 90:4763.)
158. Whitley, R. J.,, J. W. Gnann, Jr.,, D. Hinthorn,, C. Liu,, R. B. Pollard,, F. Hayden,, G. J. Mertz,, M. Oxman, and, S. J. Soong. 1992. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J. Infect. Dis. 165:450455.
159. Whitley, R. J.,, A. J. Nahmias,, S. J. Soong,, G. G. Galasso,, C. L. Fleming, and, C. A. Alford. 1980. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 66:495501.
160. Whitley, R. J.,, S. J. Soong,, R. Dolin,, G. Galasso,, L. T. Ch’ien, and, C. A. Alford. 1977. Adenine arabinoside therapy of biopsy-proven herpes simplex encephalitis. National Institute of Allergy and Infectious Disease collaborative antiviral study. N. Engl. J. Med. 297:289294.
161. Wild, K.,, T. Bohner,, A. Aubry,, G. Folkers, and, G. E. Schulz. 1997. The structures of thymidine kinase from herpes simplex virus type 1 complexed with substrates and a substrate analogue. Protein Sci. 6:20972106.
162. Wolf, D. G.,, C. T. Courcelle,, M. N. Prichard, and, E. S. Mocarski. 2001. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. USA 98:18951900.
163. Xiong, X.,, J. L. Smith, and, M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594599.
164. Xiong, X.,, J. L. Smith,, C. U. Kim,, E.-S. Huang, and, M. S. Chen. 1996. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51:15631567.
165. Yeh, R. W., and, D. M. Coen. 2005. Pharmacology of viral replication, p. 545–564. In D. E. Golan, A. H. Tashjian, Jr., E. J. Armstrong, J. M. Galanter, A. Wang Armstrong, R. A. Arnaout, and H. S. Rose (ed.), Principles of Pharmacology: the Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins, Philadelphia, PA.
166. Zuccola, H. J.,, D. J. Filman,, D. M. Coen, and, J. M. Hogle. 2000. The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C-terminus of its cognate polymerase. Mol. Cell 5:267278.


Generic image for table
Table 1.

Open reading frame designations for herpesvirus polymerases and kinases

Citation: Coen D. 2009. Antiherpesviral DNA Polymerase Inhibitors, p 1-18. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch1

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error